Long-Term Follow-Up of the Therapeutic Outcomes for XXXX With Distant @entity3 .

@entity3557 @entity1 @entity5 @entity3
UNASSIGNED: @entity3557 ( @entity3557 ) @entity1 with @entity3 ( @entity3 ) have variable clinical courses and therapeutic outcomes. Survival time after diagnosis of @entity3 may be several months to years. Long-term follow-up is necessary to determine prognostic factors for survival in @entity3557 with @entity3 . The purpose of this study was to investigate the clinical features and therapeutic outcomes of @entity3557 with @entity3 after 10 years of follow-up. The study population consisted of 70 @entity1 who underwent initial thyroidectomy before 2004 and had @entity3 beyond the locoregional neck area. Of these 70 @entity1 , 40 @entity1 were diagnosed with @entity3 before or within 9 months after initial thyroidectomy in first radioactive iodide (I) whole-body scintigraphy (group A), and 30 @entity1 were diagnosed with @entity3 during the follow-up period (group B). @entity1 with @entity3 underwent 3.7 to 7.4 GBq I therapy every 6 to 12 months. After a mean follow-up period of 10.1  0.9 years, the disease-specific mortality and remission rates were 70.0% (49/70) and 10% (7/70), respectively. The survival rates for @entity1 in groups A and B were 72.5% and 96.7% at 1 year, 47.5% and 90.0% at 5 years, 40.0% and 70.0% at 10 years, 36.4% and 41.1% at 15 years, and 35.0% and 8.0% at 20 years, respectively. The percentage of male and older @entity1 and @entity1 with larger @entity5 size was higher in the mortality group than in the survival group, whereas the percentage of @entity1 with I avid metastatic lesions (first @entity3 ) was lower in the mortality group. The percentage of @entity1 with secondary primary @entity5 was higher in group B than in group A. In the multiple regression analysis, age and male gender were independently associated with disease-specific mortality. In conclusion, after a mean follow-up of 10.1 years, the disease-specific mortality rate for @entity3557 with @entity3 was 70.0%. Older @entity1 and male @entity3557 @entity1 with @entity3 need more aggressive treatment. The timing of @entity3 diagnosis did not influence disease-specific mortality.
